Antiamyloid therapy for Alzheimer's disease--are we on the right road?

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

Authors

Eric Karran¹, John Hardy

Affiliation

¹ From Reta Lila Weston Laboratories and the Department of Molecular Neuroscience, University College London, London (E.K., J.H.), and Alzheimer's Research UK, Cambridge (E.K.) - both in the United Kingdom.

PMID: 24450897
DOI: 10.1056/NEJMe1313943

No abstract available

Publication types

Editorial
Comment

MeSH terms

Alzheimer Disease / drug therapy*
Amyloid beta-Peptides / antagonists & inhibitors*
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Male

Substances

Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
solanezumab
bapineuzumab